DIANNE HALL: Open Payments
NPI 1174906416 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$805 in 37 payments from 12 companies in 2025. Trend: 2023 $258 · 2024 $362 · 2025 $805
Food & beverage: $805
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 10 | $236 |
| Calliditas Therapeutics US Inc. | 7 | $148 |
| Amgen Inc. | 6 | $136 |
| Vifor Pharma, Inc. | 3 | $61 |
| Novo Nordisk Inc | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Novartis Pharmaceuticals Corporation | 1 | $29 |
| Alexion Pharmaceuticals, Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $17 |
Products named: TARPEYO, KRYSTEXXA, Filspari, Veltassa, Ozempic, JYNARQUE, Fabhalta, ULTOMIRIS.
Industry payments across SC — which companies pay providers there.
